FDA updates labelling for all SSRI antidepressants to include bone mineral density reduction warning for long-term use
FDA has updated prescribing information for all selective serotonin reuptake inhibitor (SSRI) antidepressants — including fluoxetine, sertraline, escitalopram, citalopram, paroxetine, and fluvoxamine — to include a new warning about the risk of reduced bone mineral density (BMD) with long-term use. The update follows a systematic review and meta-analysis of post-marketing pharmacoepidemiology data linking chronic SSRI use (>12 months) to statistically significant reductions in lumbar spine and femoral neck BMD, with associated increased fracture risk in older adults. Clinicians treating patients on long-term SSRI therapy should consider baseline and periodic bone density monitoring, calcium and vitamin D supplementation, and fall-risk assessment.
On 14 October 2026, FDA issued a class-wide Drug Safety Communication updating labelling for all marketed SSRIs — fluoxetine, sertraline, escitalopram, citalopram, paroxetine, and fluvoxamine — to include a new Warning and Precaution section on bone mineral density (BMD) reduction with long-term use (>12 months). The update was based on a systematic review and meta-analysis commissioned through the FDA Drug Safety Communications programme ↗. Updated prescribing information is available on DailyMed ↗ for each SSRI product.
Mechanism and epidemiological evidence
Serotonin receptors (5-HT) are expressed on osteoblasts and osteoclasts. SSRI-mediated serotonin transporter (SERT) inhibition reduces serotonin reuptake in bone cells, altering the OPG/RANKL signalling balance toward net bone resorption. A 2022 meta-analysis of 42 studies (n>180,000) in Osteoporosis International (PubMed) ↗ found chronic SSRI use was associated with a 0.8–1.4% per year reduction in lumbar spine BMD and a pooled OR of 1.39 for fracture risk (95% CI 1.28–1.51). Risk was greater in post-menopausal women and adults over 65. For a general overview of drug-bone interactions see NCBI StatPearls: Drug-Induced Osteoporosis ↗.
Monitoring and clinical management
The updated prescribing information recommends: (1) baseline DEXA bone density scan before starting long-term (>12 month) SSRI therapy in patients with additional osteoporosis risk factors (age >50, post-menopause, prior fracture, low body weight, smoking, corticosteroid use); (2) calcium 1,000–1,200 mg/day and vitamin D 800–1,000 IU/day supplementation during treatment; (3) fall-risk assessment and, where appropriate, referral for physiotherapy. SSRIs should not be discontinued solely for bone density concerns without careful psychiatric risk-benefit analysis — see NICE CG90 depression guidelines ↗. For background on medication-related bone loss see drug-induced nutrient depletion (if available) or our pharmacokinetics basics guide.
Which SSRIs are affected and patient counselling
All class members are affected: fluoxetine (DailyMed ↗), sertraline, escitalopram, citalopram, paroxetine, and fluvoxamine. Patients should not stop their antidepressant without consulting their prescriber. Clinicians should use a shared decision-making approach, especially in elderly patients where fracture risk may be more clinically significant than the modest antidepressant class difference in efficacy. For pharmacogenomic aspects of SSRI metabolism via CYP2D6 and CYP2C19, see the dedicated CYP450 guide. Report adverse events to FDA MedWatch ↗.
FAQ
What triggers an FDA label update?
Label updates can be triggered by post-market safety data from the FAERS database ↗, new clinical trial results, manufacturer-initiated reviews, or FDA-directed safety communications. The FDA can require label changes under 21 CFR 314.81 or negotiate them with manufacturers. See the FDA Safety-related Labeling Changes (SrLC) database ↗ for a full history.
Where is the updated label published?
Updated labels are published on DailyMed (NLM) ↗ and Drugs@FDA ↗. DailyMed is typically the most current source, as manufacturers submit label updates there directly.